In theory yes, in practice no. We would be constrained to the indication it was approved for (AML salvage therapy). All these patients have been exposed to an anthracycline earlier in their treatment so it would not be possible to treat them with an anthracycline again (no cardioprotection). Also with NPP patients you aren’t allowed to collect experimental data so no VO2Peak. The final blow is the same reason that caused the NPP to fail the first time around is still present - no doctor will pay for RC110 given they have dozens of AML trials they can put their patients into for free and get paid by the sponsor.
General Comments / Chat, page-10408
- There are more pages in this discussion • 497 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |